SUMMARY A subunit antigenoid vaccine, Ac NFUI (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that in unvaccinated patients to determine the efficacy of vaccination in preventing recurrence and spread of the virus in the community. Seven of 22 (31 %) vaccinated patients had eight recurrences after the initial clinical episode; in contrast there were 51 recurrences in 17 of 20 (85%) unvaccinated patients. Although further studies are needed, the results indicate that the vaccine may prevent recurrent episodes of herpes genitalis and thereby reduce the dissemination of this virus in the population.
Introduction
Patients and methods
The incidence of herpes genitalis continues to rise with 10 801 new cases reported in 1980 by sexually transmitted disease (STD) clinics in England and Wales-a 50% increase over the preceding five years.' As this is a latent infection with a propensity to recur, it seems likely that the periodic shedding of virus will continually increase the genital reservoir of herpes simplex virus in the community.
The efficacy of vaccine Ac NFUI, (S-) MRC The interpretation of the immunological response to vaccination-an area of enormous interest-is complicated by the apparent variability of the immunological response after the initial clinical episode in unvaccinated subjects. 12 The clinical outcome in this study, however, indicates that vaccination not only considerably alleviates personal morbidity but in the long term will help to control the apparently irreversible dissemination of this virus in the community as a whole. 
